Signifor LAR

Signifor LAR Use In Pregnancy & Lactation

pasireotide

Manufacturer:

Novartis

Distributor:

Zuellig
/
Four Star
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: There is a limited amount of data from the use of pasireotide in pregnant women. Studies in animals in which pasireotide was administered via the subcutaneous route have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Pasireotide is not recommended for use during pregnancy and in women of childbearing potential who are not using contraception (see Precautions).
Breast-feeding: It is unknown whether pasireotide is excreted in human milk. Available data in rats in which pasireotide was administered via the subcutaneous route have shown excretion of pasireotide in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). Breast-feeding should be discontinued during treatment with Signifor LAR.
Fertility: Studies in rats in which pasireotide was administered via the subcutaneous route have shown effects on female reproductive parameters (see Pharmacology: Toxicology: Preclinical safety data under Actions). The clinical relevance of these effects in humans is unknown.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in